低肿瘤负荷与2级星形细胞瘤和少突胶质细胞瘤术后观察相关:前瞻性多中心LoG-Glio登记研究结果
该前瞻性多中心登记研究分析了德国14个认证神经肿瘤中心收治的217例IDH突变型WHO 2级和3级弥漫性胶质瘤成人患者,其中169例(78%)为2级肿瘤。2级肿瘤患者中90例(53%)选择单纯观察,全切除与观察独立相关(OR 0.10;95% CI,0.04–0.22;p < 0.001);≥40岁患者辅助治疗决策偏离现行指南(OR 3.15;95% CI,1.70–5.95;p = 0.001),但年龄本身并非治疗选择的独立预测因素。
要点
- 2级胶质瘤术后管理主要取决于有无残留肿瘤,全切除者更倾向观察。
- ≥40岁患者辅助治疗决策常偏离指南,但年龄非独立预测因素。
- 研究提示指南推荐与真实世界实践存在差距,需更灵活的个体化框架。
核心结论
- 术后残留肿瘤是WHO 2级胶质瘤术后管理的主要决定因素。
- 年龄≥40岁并未独立影响临床决策。
- 研究揭示指南与真实世界实践存在差距,需更灵活的个体化治疗框架。
研究设计与样本
- 前瞻性多中心登记研究(LoG-Glio登记),纳入德国14个认证神经肿瘤中心的成人IDH突变型WHO 2级和3级弥漫性胶质瘤患者。
- 共纳入217例星形细胞瘤或少突胶质细胞瘤患者,其中169例(78%)为WHO 2级肿瘤。
- 采用多变量逻辑回归识别与观察、化疗或放疗相关的因素,并评估术后第一年指南推荐与实际治疗的一致性。
主要发现
- 2级肿瘤患者中90例(53%)选择单纯观察。
- 全切除与观察独立相关(OR 0.10;95% CI,0.04–0.22;p < 0.001)。
- ≥40岁患者辅助治疗决策偏离现行指南(OR 3.15;95% CI,1.70–5.95;p = 0.001)。
- 多变量模型中年龄本身并非治疗选择的独立预测因素。
关键数值与推荐
- 全切除与观察独立相关(OR 0.10;95% CI,0.04–0.22;p < 0.001)。
- ≥40岁患者辅助治疗决策偏离指南(OR 3.15;95% CI,1.70–5.95;p = 0.001)。
临床怎么用
- 对于WHO 2级胶质瘤术后患者,应依据残留肿瘤情况个体化决定是否观察或辅助治疗。
- 年龄≥40岁不应作为独立决定辅助治疗的因素,需结合其他临床因素综合判断。
- 临床实践中应关注指南推荐与真实世界决策的差距,推动更灵活的治疗框架。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Recent evidence-based guidelines recommend adjuvant therapy following surgery for most patients with WHO grade 2 and 3 gliomas. However, deviations from these recommendations are frequently observed in clinical practice. This study aimed to evaluate patterns of postoperative management across Germany, using multicentre registry data from certified neuro-oncology centres. METHODS: We analysed data from the ongoing multicentre registry study, which prospectively collects adult patients with IDH-mutant WHO grade 2 and 3 diffuse gliomas. Patients treated at 14 certified neuro-oncology centres were included. Multivariate logistic regression was used to identify factors associated with observation, chemotherapy, or radiotherapy. We assessed concordance between guideline recommendations and actual treatment during the first year after surgery. RESULTS: A total of 217 patients with astrocytoma or oligodendroglioma were included, of whom 169 (78%) had WHO grade 2 tumours. Observation alone was selected in 90 (53%) patients with grade 2 tumours. Gross total resection was independently associated with observation (OR 0.10; 95% CI, 0.04–0.22; p < 0.001). In patients aged ≥ 40 years, adjuvant treatment decisions deviated from current guidelines (OR 3.15; 95% CI, 1.70–5.95; p = 0.001), although age itself was not an independent predictor of treatment choice in multivariate models. CONCLUSION: The presence of residual tumour after surgery was the principal determinant of postoperative management in patients with WHO grade 2 gliomas. Age ≥ 40 years did not independently influence clinical decision-making. These findings highlight a gap between guidelines and real-world practice and underscore the need for more flexible, individualised treatment frameworks.
引用
- Ziebart A, Onken J, Nadji-Ohl M, et al. Low tumour burden is associated with observation after surgery in patients with grade 2 astrocytoma and oligodendroglioma: results from the prospective multicentre LoG-Glio registry. J Neurooncol. 2025. PMID: 41091225. doi:10.1007/s11060-025-05279-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。